

AGENDA

***Uniform Formulary Beneficiary Advisory Panel
5 April 2018 @ 0900 AM***

***Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004***

- No Administrative Meeting (BAP members report no later than 8:45 AM)
- Sign-In
- Welcome and Opening Remarks
- Public Citizen Comments
- Therapeutic Class Reviews

Members of the DHA Pharmacy Operations Division Formulary Management Branch will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations for the following drugs/drug classes during the February 2018 meeting:

- *Drug Class Reviews*
 - *Non-Insulin Diabetes Drugs: Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs) Subclass*
 - *Anti-Inflammatory Immunomodulatory Ophthalmics: Ophthalmic Immunomodulatory Agents Subclass*
 - *Osteoporosis Drugs: Parathyroid Hormone (PTH) Analogs Subclass*
 - *Corticosteroids-Immune Modulators: Adrenocorticotrophic Hormones (ACTH)*
- *Newly-Approved Drugs per CFR 199.21(g)(5)*
 - *acalabrutinib (Calquence)—Oncological Agents for Mantle Cell Lymphoma*
 - *benznidazole—Miscellaneous Anti-Infective for Chagas Disease*
 - *coagulation factor IX, recombinant (Rebinyn)—Antihemophilic Factors*
 - *dolutegravir/rilpivirine (Juluca)—Antiretrovirals*
 - *emicizumab-kxwh (Hemlibra)—Antihemophilic Factors*
 - *fluticasone propionate 93 mcg nasal spray (Xhance)—Nasal Allergy Drugs: Corticosteroids*
 - *house dust mite (HDM) allergen extract (Odactra)—Immunological Agents — Miscellaneous: Oral Agents*
 - *latanoprostene bunod ophthalmic solution (Vyzulta)—Glaucoma Agents*

- *letermovir (Prevymis)—Antivirals*
 - *minocycline ER capsules (Ximino)—Antibiotics: Tetracyclines*
 - *dapagliflozin/saxagliptin (Qtern)—Non-Insulin Diabetes Drugs: Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors*
 - *semaglutide (Ozempic)—Non-Insulin Diabetes Drugs: GLP1RAs*
 - *sodium picosulfate/magnesium oxide/anhydrous citric acid (Clenpiq)—Laxatives-Cathartics-Stool Softeners*
 - *spironolactone 25 mg/5 mL oral suspension (CaroSpir)—Diuretics*
- *Utilization Management Issues*
- *Prior Authorization Criteria—New Criteria*
 - *Corticosteroids-Immune Modulator Agents: Corticosteroids Subclass prednisone delayed release (Rayos)*
 - *Antivirals: acyclovir 5%/hydrocortisone 1% cream (Xerese); penciclovir 1% cream (Denavir); acyclovir 50 mg buccal tablet (Sitavig)*
 - *Prior Authorization Criteria—Updated Criteria*
 - *Targeted Immunomodulatory Biologics (TIBs): tofacitinib (Xeljanz/Xeljanz XR) and ixekizumab injection (Taltz)*
 - *GI-2 Miscellaneous Agents: plecanatide (Trulance)*
 - *Female Hypoactive Sexual Desire Disorder Agents: flibanserin (Addyi)*
 - *Antidepressants and Non-Opioid Pain Syndrome Agents: pregabalin (Lyrica)*
 - *Antibiotics: Tetracyclines*
- *Brand Over Generic Authorization for Sildenafil (Viagra): Prior Authorization and Co-pay Change*
- *Panel Discussions*

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.